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Abstract 5502: Adiponectin
Mediates the Effects of
Atherogenic Risk Profile on
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Purpose. Adiponectin (ADN), a biologically active protein produced by the adipose
tissue, has protective vascular effects. Accordingly, ADN plasma levels are reduced in
patients with coronary artery disease (CAD) while in heart failure ADN tends to
increase. We hypothesized that ADN plasma levels could mediate the effects of
atherogenic risk profile on the coronary microcirculation of patients with early LV
systolic dysfunction (ILVDys) not secondary to established CAD.
Methods. Plasma ADN was measured in 55 patients (age 59±1 yrs, 36 males, BMI
26.9±0.49 Kg/m2, mean±sem) with angiographically normal coronary arteries, LV
systolic dysfunction (LVEF 39.8±1.3 % range 22–54 %) but without overt heart failure
(NYHA class I–II) and in 40 age- and BMI-matched healthy controls by using a
specific Elisa (Linco Res). BMI, cholesterol and glucose profiles were assessed in all.
In a subset of 25 patients coronary microvascular function was studied by PET and
13N-Ammonia as a flow tracer. Myocardial blood flow (MBF) was measured at rest
and during i.v. dipyridamole (Dip) (0.56 mg/Kg in 4 min).
Results. ADN was 6.6±0.34 µg/ml in controls and 10.9±0.85 in ILVDys patients
(p<0.001). In patients ADN levels were inversely related with BMI (p=0.009) and
directly related with age (p=0.007), HDL Cholesterol (p=0.003) and MBF Dip (0.020).
Patients showing more severe coronary microvascular dysfunction (MBF Dip<1.42
ml/min/g, median value in patients) had significantly depressed ADN (9.7±2.3 vs
13.7±1.6, p=0.021) as compared with the remaining patients.
Conclusions. This is the first study which associates adiponectin plasma levels with
atherogenic risk profile and coronary microvascular function in patients with idiopathic
LV dysfunction. These results suggest that adiponectin signal is strongly involved in
mediating coronary vascular function independently of the presence of overt CAD or
heart failure.
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